1. Home
  2. EVC vs NKTX Comparison

EVC vs NKTX Comparison

Compare EVC & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVC
  • NKTX
  • Stock Information
  • Founded
  • EVC 1996
  • NKTX 2015
  • Country
  • EVC United States
  • NKTX United States
  • Employees
  • EVC N/A
  • NKTX N/A
  • Industry
  • EVC Broadcasting
  • NKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVC Industrials
  • NKTX Health Care
  • Exchange
  • EVC Nasdaq
  • NKTX Nasdaq
  • Market Cap
  • EVC 171.0M
  • NKTX 123.5M
  • IPO Year
  • EVC 2000
  • NKTX 2020
  • Fundamental
  • Price
  • EVC $2.07
  • NKTX $1.74
  • Analyst Decision
  • EVC
  • NKTX Strong Buy
  • Analyst Count
  • EVC 0
  • NKTX 6
  • Target Price
  • EVC N/A
  • NKTX $14.80
  • AVG Volume (30 Days)
  • EVC 185.0K
  • NKTX 422.6K
  • Earning Date
  • EVC 05-08-2025
  • NKTX 05-14-2025
  • Dividend Yield
  • EVC 9.66%
  • NKTX N/A
  • EPS Growth
  • EVC N/A
  • NKTX N/A
  • EPS
  • EVC N/A
  • NKTX N/A
  • Revenue
  • EVC $378,623,000.00
  • NKTX N/A
  • Revenue This Year
  • EVC $64.06
  • NKTX N/A
  • Revenue Next Year
  • EVC N/A
  • NKTX N/A
  • P/E Ratio
  • EVC N/A
  • NKTX N/A
  • Revenue Growth
  • EVC 23.10
  • NKTX N/A
  • 52 Week Low
  • EVC $1.58
  • NKTX $1.31
  • 52 Week High
  • EVC $2.73
  • NKTX $8.23
  • Technical
  • Relative Strength Index (RSI)
  • EVC 62.90
  • NKTX 45.11
  • Support Level
  • EVC $1.85
  • NKTX $1.70
  • Resistance Level
  • EVC $2.04
  • NKTX $1.82
  • Average True Range (ATR)
  • EVC 0.08
  • NKTX 0.10
  • MACD
  • EVC 0.02
  • NKTX -0.01
  • Stochastic Oscillator
  • EVC 86.67
  • NKTX 18.82

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: